Evaxion Biotech A/S (EVAX) Competitors

CASI Pharmaceuticals (NASDAQ:CASI) and Evaxion Biotech A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, community ranking, dividends and earnings.

Does the MarketBeat Community prefer CASI or EVAX?

CASI Pharmaceuticals received 182 more outperform votes than Evaxion Biotech A/S when rated by MarketBeat users. However, 56.67% of users gave Evaxion Biotech A/S an outperform vote while only 51.55% of users gave CASI Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
CASI Pharmaceuticals	Outperform Votes 199 51.55%	Underperform Votes 187 48.45%
Evaxion Biotech A/S	Outperform Votes 17 56.67%	Underperform Votes 13 43.33%

Do insiders and institutionals believe in CASI or EVAX?

22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 11.0% of Evaxion Biotech A/S shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by company insiders. Comparatively, 41.6% of Evaxion Biotech A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Does the media prefer CASI or EVAX?

In the previous week, CASI Pharmaceuticals and CASI Pharmaceuticals both had 1 articles in the media. CASI Pharmaceuticals' average media sentiment score of 0.67 beat Evaxion Biotech A/S's score of 0.00 indicating that Evaxion Biotech A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CASI Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evaxion Biotech A/S	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend CASI or EVAX?

CASI Pharmaceuticals presently has a consensus price target of $12.00, suggesting a potential upside of 347.76%. Evaxion Biotech A/S has a consensus price target of $11.00, suggesting a potential upside of 187.96%. Given Evaxion Biotech A/S's higher possible upside, analysts plainly believe CASI Pharmaceuticals is more favorable than Evaxion Biotech A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Evaxion Biotech A/S	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more volatility & risk, CASI or EVAX?

CASI Pharmaceuticals has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, Evaxion Biotech A/S has a beta of -0.22, suggesting that its stock price is 122% less volatile than the S&P 500.

Which has preferable valuation and earnings, CASI or EVAX?

Evaxion Biotech A/S has lower revenue, but higher earnings than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Evaxion Biotech A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$33.88M	1.06	-$26.94M	-$2.02	-1.33
Evaxion Biotech A/S	$70K	284.86	-$22.12M	-$6.76	-0.57

Is CASI or EVAX more profitable?

Evaxion Biotech A/S has a net margin of 0.00% compared to Evaxion Biotech A/S's net margin of -79.30%. Evaxion Biotech A/S's return on equity of -77.55% beat CASI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-79.30%	-77.55%	-30.64%
Evaxion Biotech A/S	N/A	-451.63%	-149.27%

Summary

CASI Pharmaceuticals and Evaxion Biotech A/S tied by winning 8 of the 16 factors compared between the two stocks.